View in EDS

Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

Saved in:
Bibliographic Details
Title: Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Authors: Tsao AS; The University of Texas MD Anderson Cancer Center, Houston, TX., Song Z; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Ho AL; Memorial Sloan Kettering Cancer Center, New York, NY., Mehnert JM; Laura and Issac Perlmutter Cancer Center, New York, NY., Ivy P; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Rockville, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Takebe N; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Ajumally R; University of Oklahoma Health Science Center, Oklahoma City, OK., Silhavy J; Illumina, Inc, San Diego, CA., Rahmanian S; Illumina, Inc, San Diego, CA., Das B; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Chen L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Karlovich C; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Lococo JS; Illumina, Inc, San Diego, CA., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; University of TX Southwestern Medical Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA.
Source: JCO precision oncology [JCO Precis Oncol] 2025 Oct; Vol. 9, pp. e2500119. Date of Electronic Publication: 2025 Oct 09.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41066729
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tsao+AS%22">Tsao AS</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Song+Z%22">Song Z</searchLink>; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Ho+AL%22">Ho AL</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Mehnert+JM%22">Mehnert JM</searchLink>; Laura and Issac Perlmutter Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Ivy+P%22">Ivy P</searchLink>; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Gray+RJ%22">Gray RJ</searchLink>; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Wang+V%22">Wang V</searchLink>; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22McShane+LM%22">McShane LM</searchLink>; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Rubinstein+LV%22">Rubinstein LV</searchLink>; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Patton+DR%22">Patton DR</searchLink>; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Rockville, MD.<br /><searchLink fieldCode="AU" term="%22Williams+PM%22">Williams PM</searchLink>; Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Hamilton+SR%22">Hamilton SR</searchLink>; City of Hope National Medical Center, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Takebe+N%22">Takebe N</searchLink>; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Ajumally+R%22">Ajumally R</searchLink>; University of Oklahoma Health Science Center, Oklahoma City, OK.<br /><searchLink fieldCode="AU" term="%22Silhavy+J%22">Silhavy J</searchLink>; Illumina, Inc, San Diego, CA.<br /><searchLink fieldCode="AU" term="%22Rahmanian+S%22">Rahmanian S</searchLink>; Illumina, Inc, San Diego, CA.<br /><searchLink fieldCode="AU" term="%22Das+B%22">Das B</searchLink>; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Chen+L%22">Chen L</searchLink>; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Karlovich+C%22">Karlovich C</searchLink>; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD.<br /><searchLink fieldCode="AU" term="%22Lococo+JS%22">Lococo JS</searchLink>; Illumina, Inc, San Diego, CA.<br /><searchLink fieldCode="AU" term="%22Tricoli+JV%22">Tricoli JV</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Conley+BA%22">Conley BA</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Arteaga+CL%22">Arteaga CL</searchLink>; University of TX Southwestern Medical Center, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Harris+LN%22">Harris LN</searchLink>; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22O'Dwyer+PJ%22">O'Dwyer PJ</searchLink>; University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Chen+AP%22">Chen AP</searchLink>; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Massachusetts General Hospital, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101705370%22">JCO precision oncology</searchLink> [JCO Precis Oncol] 2025 Oct; Vol. 9, pp. e2500119. <i>Date of Electronic Publication: </i>2025 Oct 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101705370 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-4284 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224734284%22">24734284 </searchLink><i>NLM ISO Abbreviation: </i>JCO Precis Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41066729
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/PO-25-00119
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e2500119
    Titles:
      – TitleFull: Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tsao AS
      – PersonEntity:
          Name:
            NameFull: Song Z
      – PersonEntity:
          Name:
            NameFull: Ho AL
      – PersonEntity:
          Name:
            NameFull: Mehnert JM
      – PersonEntity:
          Name:
            NameFull: Ivy P
      – PersonEntity:
          Name:
            NameFull: Gray RJ
      – PersonEntity:
          Name:
            NameFull: Wang V
      – PersonEntity:
          Name:
            NameFull: McShane LM
      – PersonEntity:
          Name:
            NameFull: Rubinstein LV
      – PersonEntity:
          Name:
            NameFull: Patton DR
      – PersonEntity:
          Name:
            NameFull: Williams PM
      – PersonEntity:
          Name:
            NameFull: Hamilton SR
      – PersonEntity:
          Name:
            NameFull: Takebe N
      – PersonEntity:
          Name:
            NameFull: Ajumally R
      – PersonEntity:
          Name:
            NameFull: Silhavy J
      – PersonEntity:
          Name:
            NameFull: Rahmanian S
      – PersonEntity:
          Name:
            NameFull: Das B
      – PersonEntity:
          Name:
            NameFull: Chen L
      – PersonEntity:
          Name:
            NameFull: Karlovich C
      – PersonEntity:
          Name:
            NameFull: Lococo JS
      – PersonEntity:
          Name:
            NameFull: Tricoli JV
      – PersonEntity:
          Name:
            NameFull: Conley BA
      – PersonEntity:
          Name:
            NameFull: Arteaga CL
      – PersonEntity:
          Name:
            NameFull: Harris LN
      – PersonEntity:
          Name:
            NameFull: O'Dwyer PJ
      – PersonEntity:
          Name:
            NameFull: Chen AP
      – PersonEntity:
          Name:
            NameFull: Flaherty KT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2025 Oct
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-4284
          Numbering:
            – Type: volume
              Value: 9
          Titles:
            – TitleFull: JCO precision oncology
              Type: main
ResultId 1